21 / 39
Investigator-Assessed Duration of Response
Motzer et al.
N Engl J Med
. 2015;373(19):1803-1813.
0
16
32
64
48
80
Time (Weeks)
96
112
128
Responders
Ongoing response
First response
Off treatment
Nivolumab
Everolimus
On treatment
.